Pipeline

    Company Product Type Indication Development stage
    Basilea Pharmaceutica International Ltd. Ceftobiprole Antibacterial drug Community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia) 9Marketed
    Basilea Pharmaceutica International Ltd. Ceftobiprole Antibacterial drug Acute bacterial skin and skin structure infections, Staphylococcus aureus bacteremia 7Phase III
    Motif BioSciences, Inc. Iclaprim Antibacterial drug HABP/VABP 7Phase III
    Motif BioSciences, Inc. Iclaprim Antibacterial drug ABSSSI 7Phase III
    Polyphor Ltd Murepavadin Antibacterial drug HAP, VAP 7Phase III
    NovaBiotics Ltd Lynovex® oral Other Cystic Fibrosis 6Phase II
    NovaBiotics Ltd Novexatin® Non Antibacterial drug Onychomycosis 6Phase II
    MaaT Pharma maaT031 Other Bone and Joint Infectious 6Phase II
    MaaT Pharma MaaT011 Other Acute Myeloid Leukemia 6Phase II
    Destiny Pharma plc XF-73 Antibacterial drug Post-surgical nasal decolonisation 6Phase II
    DA VOLTERRA DAV132 Non Antibacterial drug Prevention of C.difficile infections 6Phase II
    Debiopharm International afabicin (Debio 1450) Antibacterial drug ABSSSI, Bone & Joint Infections (BJIs) 6Phase II
    AntibioTx A/S ATx201 Antibacterial drug Antibiotic - skin infections 6Phase II
    ALLECRA THERAPEUTICS cefepime/AAI101 Antibacterial drug cUTI, cIAI, HAP 6Phase II
    Arsanis Biosciences GmbH ASN100 Prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients 6Phase II
    AiCuris Anti-infective Cures GmbH AIC499 - a Superior Gram-negative Resistance Breaker Antibacterial drug Gram-negative resistance breaker 5Phase I
    Combioxin SA CAL02 Non Antibacterial drug Severe infections 5Phase I
    ALAXIA ALX-009 Antibacterial drug Cystic Fibrosis 5Phase I
    NovaBiotics Ltd Lynovex® inhaled Other Cystic Fibrosis 4IND/CTA ready
    NovaBiotics Ltd Luminaderm® Antibacterial drug MRSA 3Pre-clinical
    NovaBiotics Ltd Novarifyn® Antibacterial drug Antibacterial Peptide 3Pre-clinical
    NovaBiotics Ltd Nylexa™ Other Resistance breaker 3Pre-clinical
    NovaBiotics Ltd Novamycin® Non Antibacterial drug Invasive Fungal Disease 3Pre-clinical
    Hypharm GmbH HY-133 Antibacterial drug nasal colonization with MRSA 3Pre-clinical
    Auspherix Ltd Novel class of organogold antibiotics Antibacterial drug cUTI 3Pre-clinical
    Centauri Therapeutics Ltd Pseudomonas Aeruginosa specific Inhibitor Other Undisclosed 3Pre-clinical
    Centauri Therapeutics Ltd Broad spectrum Gram negative Inhibitor Other Undisclosed 3Pre-clinical
    NOSOPHARM NOSO-502 Antibacterial drug MDR Enterobacteriaceae infections 3Pre-clinical
    Neem Biotech Ltd NX-AS-401 Non Antibacterial drug Chronic respiratory infections in cystic fibrosis 3Pre-clinical
    Neem Biotech Ltd NX-AS-911 Non Antibacterial drug Chronic wounds 3Pre-clinical
    Motif BioSciences, Inc. Iclaprim Antibacterial drug Staphylococcus aureus Lung Infections Among Cystic Fibrosis Patients 3Pre-clinical
    Eligo Bioscience EB014 Antibacterial drug Multi-drug resistant Enterobacteriaceae 3Pre-clinical
    Destiny Pharma plc XF-70 Antibacterial drug Bacterial biofilm-infections 3Pre-clinical
    Destiny Pharma plc XF-70 Antibacterial drug Dermal burn wound infections 3Pre-clinical
    Destiny Pharma plc XF-73 Antibacterial drug Hospital pneumonia/ventilator-associated pneumonia (VAP) 3Pre-clinical
    Madam Therapeutics BV SAAP148 Antibacterial drug Diabetic foot ulcers, burns and MRSA carriership 3Pre-clinical
    BioVersys AG Adjuvant reversing resistance and potentiating Ethionamide activity in Tuberculosis Non Antibacterial drug Tuberculosis 3Pre-clinical
    ABAC therapeutics ABAC-39,877 Antibacterial drug Infections by MDR/XDR A baumannii, including ColistinR and CarbapenemR 3Pre-clinical
    VIBIOSPHEN Sativa Non Antibacterial drug Pulmonary infection, UTI 3Pre-clinical
    Northern Antibiotics Oy (Ltd) Improved derivatives of polymyxin B Antibacterial drug primary indication, cUTI caused by MDR Gram-negatives 3Pre-clinical
    SetLance srl SET-M33 Antibacterial drug Antimicrobial peptide 3Pre-clinical
    Arsanis Biosciences GmbH ASN200 Prevention and treatment of E. coli infections 3Pre-clinical
    Arsanis Biosciences GmbH ASN300 Prevention and treatment of K. pneumoniae infections 3Pre-clinical
    QureTech Bio AB Mtb Tolerance Inhibitor Antibacterial drug MDR Tuberculosis 3Pre-clinical
    ANTABIO S.A.S ANTXXXX Non Antibacterial drug hospital-acquired infections caused by carbapenem-resistant Enterobacteriaceae (CRE) 3Pre-clinical
    Redx Anti-Infectives Ltd Novel bacterial Topoisomerase Inhibitor Antibacterial drug Hospital acquired Pneumonia 2Lead opt
    Redx Anti-Infectives Ltd Novel tri-cyclic topoisomerase inhibitor Antibacterial drug Complicated skin and skin structure infections 2Lead opt
    BioVersys AG Anti Virulence in Gram negative bacteria Non Antibacterial drug gram negative infections 2Lead opt
    Polyphor Ltd OMPTA Antibacterial drug HAP, VAP, UTI, IAI, other 2Lead opt
    Polyphor Ltd Murepavadin (inhaled) Antibacterial drug Cystic Fibrosis; Bronchiectasis 2Lead opt
    BioVersys AG Anti-Biofilm for Staphylococcus aureus Non Antibacterial drug systemic 2Lead opt
    QureTech Bio AB Chlamydia Antibacterial drug Genital Chlamydia infection 2Lead opt
    QureTech Bio AB GmP's against VRE and MRSA Antibacterial drug VRE and MRSA 2Lead opt
    ANTABIO S.A.S ANTYYYY Non Antibacterial drug chronic Pseudomonas infections in Cystic Fibrosis patients 2Lead opt
    Karveel Pharmaceuticals SNP021062 Antibacterial drug Undisclosed 1Undisclosed
    Karveel Pharmaceuticals KVL-## Non Antibacterial drug Undisclosed 1Undisclosed
    Debiopharm International Debio1453 Antibacterial drug N. gonorrhoeae 1Discovery
    DA VOLTERRA DAV121 Non Antibacterial drug Prevention of carbapenem resistance emergence 1Discovery
    QureTech Bio AB Chlamydia Antibacterial drug Trachoma, Chlamydia eye infection 1Discovery

    The stage of development is approximate; please refer to each company’s website for updated information.